LOGIN  |  REGISTER
Recursion

iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023

May 23, 2023 | Last Trade: US$1.24 0.09 -6.44

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group LLC (“Maxim”) and M-Vest, a division of Maxim, on Thursday, June 1, 2023.

Ms. Curley will participate in a fireside chat with Allen Klee, Research Analyst at Maxim, at 11:00 a.m. ET. To attend, please register here.

For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Maxim representative, or send an email to KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..

About iSpecimen

iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Phil Carlson / Erika Kay
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contacts
KCSA Strategic Communications
Raquel Cona / Michaela Fawcett
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page